Atezolizumab (MPDL3280A) is a selective humanized monoclonalIgG1antibody against programmed death ligand 1 (PD-L1), used forcancerresearch.

Atezolizumab (0, 2.5, 5, 10, 20, and 40 μg/ml; 24 hours; HOS and 143B cells) inhibits proliferation and induces immune-independent apoptosis of osteosarcoma cells^[1].
Atezolizumab impairs the function of mitochondria to cause the imbalance between oxidants and antioxidants. Atezolizumab induces mitochondria-related apoptosis of osteosarcoma cells by activating JNK pathway. Atezolizumab (10 μg/ml; 24 hours; HOS and 143B cells) induces autophagy in osteosarcoma cells^[1].

144590.50

Liquid

1380723-44-3

阿特珠单抗；阿替利珠单抗

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.